Dr. Lakshmi Venkataraman
Written by Dr. Lakshmi Venkataraman, MD
Medically Reviewed by The Medindia Medical Review Team on March 21, 2019 at 5:50 PM
Health In Focus
RSS Email Print This Page Comment bookmark

Highlights:
  • Radiomics is a science that uses algorithms to extract patterns from CT scan images which are not visible to the naked eye. These unique patterns are quantitatively assessed by using artificial intelligence to identify those patients who are likely to respond to chemotherapy in non-small cell lung cancer
  • The standard first-line treatment of advanced-stage non-small cell lung cancer (NSCLC) is platinum-based chemotherapy. However, only about 25 percent of patients respond well to this therapy, and currently there is no way to predict who will respond and who will not
  • CT scans are routinely used in cancer patients to stage disease and monitor response to treatment. The field of radiomics can, therefore, be ideally used to identify patients who are unlikely to respond to chemo so that alternative treatments such as radiotherapy and immunotherapy can be planned for them

Radiomics can help identify those patients with advanced non-small cell lung cancer (NSCLC) who are likely to respond to chemotherapy and who may not, according to the joint study conducted recently at the Department of Biomedical Engineering, Case Western Reserve University School of Engineering in Cleveland, Ohio and Department of Internal Medicine at Cleveland Clinic.

"Our aim in this study was to determine whether an early prediction of response to chemotherapy is possible by using computer-extracted measurements of patterns both within and outside the lung nodule, along with the shape of the nodule, on baseline CT scans," said Mohammadhadi Khorrami, M.S., a Ph.D. candidate from the Department of Biomedical Engineering, Case Western Reserve University School of Engineering in Cleveland, Ohio, who, along with Monica Khunger, M.D., from the Department of Internal Medicine at Cleveland Clinic, led the study.
Radiomics Can Predict Patients’ Response To Chemotherapy

The findings of the study appear in the journal Radiology: Artificial Intelligence.

Predicting Response to Treatment in NSCLC Using Radiomics

The study team set out to identify the role of radiomic patterns both within the lung tumor as well as a peri-tumor area to predict response to chemotherapy, overall survival as well as the risk of progression in patients with non-small cell lung cancer (NSCLC).
  • The study included 125 patients treated in Cleveland Clinic with pemetrexed-based platinum doublet cancer treatment
  • In this randomized study, the participants were grouped randomly into a training set and validation set. The training set had 53 patients with NSCLC, while the validation set had 72 patients
  • The training set included equal numbers of patients who had responded to NSCLC chemotherapy (responders) and an equal number of patients who had not (non-responders)
  • A computer analyzed the CT scans of lung cancer to pinpoint unique patterns of heterogeneity both inside as well as the area around the tumor
  • These image patterns were then matched against the CT scans of both responders and non-responders and these unique feature patterns present were then used to train a machine learning system to identify those patients who were likely to respond to chemotherapy
  • The results demonstrated that the radiomic patterns derived from both within the tumor and the area around the tumor were able to differentiate between patients who responded to chemotherapy from those who showed no response
  • Also, the radiomic features were able to predict the rate of progression and overall patient survival
  • When patterns within the tumor alone were analyzed, the accuracy of prediction was 0.68 but when patterns both within the tumor and peri-tumor area were analyzed, the accuracy went up to 0.77
The findings of the study suggest that analysis of radiomic patterns both within the tumor and the area surrounding the tumor can accurately predict patients who are likely to respond to chemotherapy in NSCLC as well as the rate of progression and overall survival.


"This is the first study to demonstrate that computer-extracted patterns of heterogeneity, or diversity, from outside the tumor were predictive of response to chemotherapy," Dr. Khunger said. "This is very critical because it could allow for predicting in advance of therapy which patients with lung cancer are likely to respond or not. This, in turn, could help identify patients who are likely to not respond to chemotherapy for alternative therapies such as radiation or immunotherapy."

Although, the possible reason for the difference in response to chemotherapy is not clear, the study team believes that increased fibrous tissue content of tumor may make it more responsive to chemotherapy.

Summary

Analyzing unique radiomic patterns of CT images can help predict patient response to chemotherapy in lung cancer as well as rate of progression and risk of tumor recurrence. This information will help treating doctors plan management accordingly.

Reference:
  1. Combination of Peri- and Intratumoral Radiomic Features on Baseline CT Scans Predicts Response to Chemotherapy in Lung Adenocarcinoma - (https://pubs.rsna.org/doi/10.1148/ryai.2019180012)


Source: Medindia

Recommended Reading

Non-small Cell Lung Cancer: Combination Therapy Doubles Survival Rate
The immunotherapy drug pembrolizumab, when combined with chemotherapy, doubles survival in patients with non-squamous non-small cell lung cancer (NSNSCLC) when compared to chemotherapy alone.
READ MORE
Artificial Intelligence Can Reduce Lung Cancer Screening False Positives
Artificial intelligence (AI) can substantially reduce false positive screens for lung cancer, reveals a new study.
READ MORE
Method to Overcome False Positives in CT Imaging for Lung Cancer Discovered
False-positive lung cancer screening results increase health care costs and may lead to unintentional physician-caused injury and mortality.
READ MORE
Small Cell Lung Cancer Treatment: Same Chemo Treatment can be Given to Both 60 and 70-year-olds
Chemotherapy given to people over the age of 60 with limited-stage small cell lung cancer can also be given to 70-year-olds, finds a new study. The survival and toxicity levels were found to be the same in both the groups.
READ MORE
Chemotherapy
‘Chemo’ means medicine or ‘drug’; ‘therapy’ means ‘treatment’. Chemotherapy refers to the use of cytotoxic drugs in cancer treatment.
READ MORE
Chemotherapy Drugs
Chemotherapy drugs perform like ‘magic bullets’ to destroy cancer cells in the body.
READ MORE
Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia (CLL) is one of the most common types of adult leukemia and is considered as one of the ‘good cancers’.
READ MORE
Hodgkins Lymphoma
Hodgkins lymphoma or Hodgkins disease has the distinction of being the first cancer to be cured by chemotherapy or by radiotherapy.
READ MORE
Male Breast Cancer
Most cases of male breast cancer are diagnosed between the ages of 60 and 70 years. Treatment of male breast cancer often involves surgery.
READ MORE
Non-Hodgkins Lymphoma
Non Hodgkins Lymphoma is a cancer that affects the lymph tissues. It is made up of a wide array of subtypes.
READ MORE
Peritoneal Cancer
Peritoneal cancer is a rare cancer that develops in the peritoneum. Peritoneal cancers may be primary or secondary and symptoms of peritoneal cancer are vague.
READ MORE
Rhabdomyosarcoma
Rhabdomyosarcoma is a rare type of cancer affecting the striated muscles. It mostly occurs in children.
READ MORE
Tumor Lysis Syndrome
Tumor lysis syndrome is a collection of metabolic abnormalities due to the tumor cell lysis in patients with treatment for malignancies.
READ MORE

Most Popular on Medindia

Fongitar (Zinc Pyrithionone)

Fongitar (Zinc Pyrithionone)

Drug - Food Interactions

Drug - Food Interactions

A-Z Drug Brands in India

A-Z Drug Brands in India

More News on:

Chronic Lymphocytic LeukemiaHodgkins LymphomaNon-Hodgkins LymphomaChemotherapyChemotherapy DrugsPeritoneal CancerRhabdomyosarcomaMale Breast CancerTumor Lysis Syndrome